Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSK | P43235 | 5/20 | 0.54 |
| ▸ | CTSB | P07858 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.49 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100570 | 0.92 | CTSS (0.56) | CTSSCTSKCTSBCTSLPSMB1 | |
| SCHEMBL30100571 | 0.90 | CTSS (0.58) | CTSSCTSKCTSBCTSLPSMB1 | |
| SCHEMBL18239621 | 0.89 | KLK5 (0.52) | CTSSCTSKCTSBCTSLSYK | |
| SCHEMBL23629869 | 0.87 | CTSL (0.58) | CTSSCTSKCTSBCTSLTACR1 | |
| SCHEMBL23629866 | 0.87 | CTSL (0.58) | CTSSCTSKCTSBCTSLTACR1 | |
| SCHEMBL25908037 | 0.87 | ALDH1A1 (0.53) | CTSSCTSKCTSBCTSLSYK | |
| SCHEMBL6932926 | 0.87 | ALDH1A1 (0.53) | CTSSCTSKCTSBCTSLSYK | |
| SCHEMBL11781435 | 0.86 | CTSL (0.57) | CTSSCTSKCTSBCTSLTACR1 | |
| SCHEMBL31364169 | 0.86 | CTSS (0.59) | CTSSCTSKCTSBCTSLPSMB1 | |
| SCHEMBL30100564 | 0.86 | CTSS (0.61) | CTSSCTSKCTSBCTSLPSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-117801107-A | Benzazepine derivatives, conjugates containing same and application thereof | 上海迪诺医药科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-112714649-A | Novel cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2021-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | CTSS 3687/4885CTSK 2945/4885CTSB 2033/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | CTSS 3192/4885CTSK 2449/4885CTSB 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.